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Sir,
We read with interest the article by Nieuwenhuis et al,
‘Evaluation of management of desmoids tumours associated with
familial adenomatous polyposis in Dutch patients’ (Nieuwenhuis
et al, 2011). Similar studies have been performed in other
polyposis registries (Church, 1995; Clark and Phillips, 1996).
Because of the rarity of these tumours and their variable course
(30% growth and regression, 10% aggressive growth, 50% stable
course, 10% spontaneous resolution) (Church, 1995), it is difficult
to assess the effect of any one particular therapy.
Although the study by Nieuwenhuis et al provides valuable
information on this rare condition in one cohort of patients, a
number of issues are raised. It is not clear from the presented data
what the indications were for ‘primary surgery’ for intra-
abdominal tumours. In the introduction, the authors describe a
‘step-wise approach’ to managing desmoids, starting with NSAIDs
and antioestrogens, and escalating treatment if disease progresses
(Sturt and Clark, 2006). It is not clear whether those undergoing
surgery had medical therapy previously or not, and, if not, why
they had not been managed using this accepted approach.
Generally surgery is reserved for more problematic intra-
abdominal desmoids, those that do not respond to medical
therapy. It is unclear from this paper exactly what operations
were performed. Sometimes it is only possible to bypass or
proximally de-function the bowel obstructed by the tumour or to
drain desmoid necrosis. Although it is useful to see the outcomes
following surgical or medical therapy, a comparison such as the
one presented here is only valid if the same indications are used
for both treatments, which is unlikely to be the case here.
Progress-free period has been defined as the period from
identification of desmoids to the development of symptoms.
Certainly, in intra-abdominal desmoids it would be difficult to
attribute all symptoms to desmoid disease. How the progression
was objectively measured has not been mentioned in the
discussion. Did the authors use only clinical evaluation or was
any form of imaging used? The patients detailed in Table 3
represent the minority with aggressive disease, some of whom still
die as a result of desmoid despite all the treatments described.
We wholeheartedly support the authors’ statement that ‘cluster-
ing of desmoid patients in some specialised referral centres will
benefit treatment and follow-up and enables further research into
this controversial topic’. Only such centralisation and co-operation
between centres will allow any progress in the understanding of
these rare tumours and development of effective treatment
strategies.
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